Extended-release trazodone in the treatment of major depressive disorder
Articles > Review · 2019
Authors: Oguz Karamustafalioglu, Nesrin Dilbaz, Ali Caykoylu, Tunc Alkin, Ali Saffet GÖNÜL, Murad Atmaca
ANADOLU PSIKIYATRI DERGISI-ANATOLIAN JOURNAL OF PSYCHIATRY, Journal Indexed in SCI Expanded, International, 2019, vol 20, pp 453-453
Summary
Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants.